[go: up one dir, main page]

DE60008524D1 - Furanonderivate als inhibitoren von cathepsin s - Google Patents

Furanonderivate als inhibitoren von cathepsin s

Info

Publication number
DE60008524D1
DE60008524D1 DE60008524T DE60008524T DE60008524D1 DE 60008524 D1 DE60008524 D1 DE 60008524D1 DE 60008524 T DE60008524 T DE 60008524T DE 60008524 T DE60008524 T DE 60008524T DE 60008524 D1 DE60008524 D1 DE 60008524D1
Authority
DE
Germany
Prior art keywords
furanon
cathepsin
inhibitors
derivatives
furanon derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60008524T
Other languages
English (en)
Other versions
DE60008524T2 (de
Inventor
Martin Quibell
Steven Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir UK Ltd
Peptimmune Inc
Original Assignee
Medivir UK Ltd
Peptimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir UK Ltd, Peptimmune Inc filed Critical Medivir UK Ltd
Application granted granted Critical
Publication of DE60008524D1 publication Critical patent/DE60008524D1/de
Publication of DE60008524T2 publication Critical patent/DE60008524T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
DE60008524T 1999-05-18 2000-05-18 Furanonderivate als inhibitoren von cathepsin s Expired - Fee Related DE60008524T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9911417.5A GB9911417D0 (en) 1999-05-18 1999-05-18 Furanone derivatives as inhibitors of cathepsin s
GB9911417 1999-05-18
PCT/GB2000/001894 WO2000069855A2 (en) 1999-05-18 2000-05-18 Furanone derivatives as inhibitors of cathepsin s

Publications (2)

Publication Number Publication Date
DE60008524D1 true DE60008524D1 (de) 2004-04-01
DE60008524T2 DE60008524T2 (de) 2004-12-23

Family

ID=10853598

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60008524T Expired - Fee Related DE60008524T2 (de) 1999-05-18 2000-05-18 Furanonderivate als inhibitoren von cathepsin s

Country Status (16)

Country Link
EP (2) EP1178986B1 (de)
JP (1) JP2002544274A (de)
AR (1) AR024040A1 (de)
AT (1) ATE260274T1 (de)
AU (1) AU763694B2 (de)
BR (1) BR0010553A (de)
CA (1) CA2374297A1 (de)
DE (1) DE60008524T2 (de)
DK (1) DK1178986T3 (de)
ES (1) ES2215048T3 (de)
GB (1) GB9911417D0 (de)
IL (2) IL146409A0 (de)
MX (1) MXPA01011872A (de)
MY (1) MY130768A (de)
PT (1) PT1178986E (de)
WO (1) WO2000069855A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004512261A (ja) * 2000-05-17 2004-04-22 メディヴァー　ユーケイ　リミテッド 分枝鎖アミノ酸
JP2004520439A (ja) * 2000-11-17 2004-07-08 メディヴィル・アクチボラグ システインプロテアーゼインヒビター
US7064123B1 (en) 2000-12-22 2006-06-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
CA2436462C (en) * 2001-01-17 2011-07-05 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
EP1362042A1 (de) * 2001-01-17 2003-11-19 Amura Therapeutics Limited Cyclische 2-carbonylaminoketone als inhibitoren von cruzipain und anderen cysteinproteasen
IL156776A0 (en) 2001-01-17 2004-02-08 Amura Therapeutics Ltd Inhibitors of cruzipain and other cysteine proteases
US7132449B2 (en) * 2001-01-17 2006-11-07 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
KR20040044920A (ko) 2001-09-14 2004-05-31 아벤티스 파마슈티칼스 인크. 카뎁신 억제제로서 신규한 화합물 및 조성물
JP2005508979A (ja) * 2001-10-29 2005-04-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼの可逆性インヒビターとして有用な化合物
JP2005514353A (ja) 2001-11-14 2005-05-19 アベンティス・ファーマスーティカルズ・インコーポレイテツド カテプシンｓ阻害剤としてのオリゴペプチドおよびそれらを含有する組成物
US7087604B2 (en) 2002-03-08 2006-08-08 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JP2006504651A (ja) * 2002-07-16 2006-02-09 アミュラ テラピューティクス リミテッド 生物活性化合物
TWI335311B (en) 2002-09-24 2011-01-01 Novartis Ag Organic compounds
US7297714B2 (en) * 2003-10-21 2007-11-20 Irm Llc Inhibitors of cathepsin S
WO2005082876A1 (en) * 2004-03-01 2005-09-09 Medivir Uk Ltd C-5 substituted furanone dipeptide cathepsin s inhibitors
WO2006064286A1 (en) * 2004-12-13 2006-06-22 Medivir Uk Ltd Cathepsin s inhibitors
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
EP1916248A1 (de) * 2006-10-24 2008-04-30 Medivir Ab Furanonderivate als Inhibitoren der Cysteinprotease
KR20090115944A (ko) 2007-02-28 2009-11-10 사노피-아벤티스 영상 프로브
WO2009087379A2 (en) 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
SG10201406263SA (en) 2008-06-20 2015-02-27 Novartis Ag Paediatric compositions for treating multiple sclerosis
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2111930A1 (en) * 1992-12-25 1994-06-26 Ryoichi Ando Aminoketone derivatives
PT912601E (pt) * 1996-04-22 2004-04-30 Massachusetts Inst Technology Supressao da resposta imune via inibicao da catepsina s
AR013079A1 (es) * 1997-05-06 2000-12-13 Smithkline Beecham Corp Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios

Also Published As

Publication number Publication date
EP1413580A1 (de) 2004-04-28
IL146409A (en) 2005-11-20
EP1178986A2 (de) 2002-02-13
AU763694B2 (en) 2003-07-31
DK1178986T3 (da) 2004-07-05
BR0010553A (pt) 2002-07-02
DE60008524T2 (de) 2004-12-23
JP2002544274A (ja) 2002-12-24
GB9911417D0 (en) 1999-07-14
ATE260274T1 (de) 2004-03-15
MXPA01011872A (es) 2003-09-04
AU4772200A (en) 2000-12-05
CA2374297A1 (en) 2000-11-23
WO2000069855A2 (en) 2000-11-23
ES2215048T3 (es) 2004-10-01
WO2000069855A3 (en) 2001-02-08
EP1178986B1 (de) 2004-02-25
IL146409A0 (en) 2002-07-25
AR024040A1 (es) 2002-09-04
PT1178986E (pt) 2004-07-30
MY130768A (en) 2007-07-31

Similar Documents

Publication Publication Date Title
DE60008524D1 (de) Furanonderivate als inhibitoren von cathepsin s
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
DE60019577D1 (de) 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
ATE330954T1 (de) Quinazolin-derivate als vegf-hemmer
ATE256127T1 (de) Betacarbolinderivate als phosphodiesterase- inhibitoren
DE60134094D1 (de) C7-taxanester als antitumormittel
ATE339404T1 (de) Nitrilderivate als cathepsin k hemmer
DE69930518D1 (de) Als antikrebsmittel verwendbare alkinyl-substituierte chinolin-2-on-derivate
ID29550A (id) Quinolinakarboksamida sebagai agen-agen antivirus
DE60032601D1 (de) Als antikrebsmittel verwendbare heterocyklische derivate
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
DE60106252D1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
ATE315036T1 (de) 2,4-diaminopyrimidinderivate als immunosuppressiva
ATE338021T1 (de) Substituierte 2-dialkylaminoalkylbiphenyl- derivate
ATE270270T1 (de) Neuartige phenylalkyloxy-phenyl-derivate
DE60203529D1 (de) Indolderivate als cox-ii-inhibitoren
DE60114852D1 (de) Chinazolin-derivate als alpha-1 adrenerge antagonisten
EP1078926A4 (de) Pyranderivate
DE60218213D1 (de) Pyridyloxyalkancarbonsäureamid-derivate verwendbar als fungizide
ATE428420T1 (de) Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer
DE50011908D1 (de) 16-hydroxyestratriene als selektiv wirksame estrogene
DE60003072D1 (de) Thiazolidindion-derivate als antidiabetika
DE60214138D1 (de) Isoxazolin-derivate als antidepressiva
ATE300945T1 (de) Isoxazolderivate als phosphodiesterase vii-hemmer
DE60201463D1 (de) Indanon-Derivate als Duftstoffe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee